Results 291 to 300 of about 223,964 (346)
Some of the next articles are maybe not open access.

Antifungal agents

Medical Journal of Australia, 2007
The four main classes of antifungal drugs are the polyenes, azoles, allylamines and echinocandins. Clinically useful "older" agents include topical azole formulations (for superficial yeast and dermatophyte infections), first-generation triazoles (fluconazole and itraconazole, for a range of superficial and invasive fungal infections), amphotericin B ...
Sharon C A, Chen, Tania C, Sorrell
openaire   +2 more sources

Antifungal Agents

2015
Antifungal drugs used to treat serious fungal disease fall primarily into three drug classes. These classes include the azoles, echinocandins, and polyenes. Both azoles and polyenes target the cell membrane while echinocandins specifically target cell-wall synthesis. Amphotericin B is the primary drug in the polyene arsenal and is considered fungicidal,
Peter Davey   +3 more
  +5 more sources

New antifungal agents

Hospital Medicine, 2004
With the relentless increase in invasive fungal infections, particularly in critically ill and immunocompromised patients, it is good to know that there are new additions to the antifungal armamentarium. These include not only new formulations of existing drugs and the development of new triazole agents, but also the introduction of a new class of ...
Anjali, Shetty, Rosemary A, Barnes
openaire   +4 more sources

Antifungal Agent

Science, 1961
From the soil of the San Joaquin Valley a fungus has been isolated, an extract of which inhibits the growth of Coccidioides immitis on Sabouraud's medium. An acute toxicity study in mice indicates a certain tolerance of the extract. Tentative identification indicates that the fungus is a penicillium.
M C, EGEBERG, A F, ELCONIN, R O, EGEBERG
openaire   +2 more sources

New antifungal agents

Seminars in Respiratory Infections, 2002
Treatment of fungal infections is an area of increasing concern. This is because of the complexity of underlying illness in affected patients as well as the limited number of antifungal agents available for use. Current strategies focus on prevention of these infections in patients at high risk; however, this has the potential to lead to the emergence ...
Irene, Lu   +2 more
openaire   +4 more sources

Antifungal agents, WO2009025733

Expert Opinion on Therapeutic Patents, 2009
The incidence and prevalence of serious mycoses continues to be a public health problem. These infections are an important cause of morbidity and mortality, especially in immunocompromised patients. The present patent deals with isolation and characterization of a 'pure' mixture of two novel isoxazolidinone-containing natural products from two new ...
Pore Vandana, Sudhir   +2 more
openaire   +2 more sources

Sordaricin antifungal agents

Bioorganic & Medicinal Chemistry Letters, 2003
Compounds based on sordaricin were prepared via organometallic addition onto a fully protected sordaricin aldehyde. The fungal growth inhibition profiles for these compounds were established and the results are presented here. The synthesis of homologated sordaricin as well as ether and ester derivatives is presented, and structural rearrangement ...
Claude A, Quesnelle   +11 more
openaire   +2 more sources

Newer antifungal agents

The Indian Journal of Pediatrics, 2004
Invasive fungal infections have evolved into significant causes of morbidity and mortality in premature infants, immunocompromised children, and patients receiving immunosuppressive agents. Since the discovery in 1955, amphotericin B has been the cornerstone of antifungal treatment.
Walid, Abuhammour, Eyassu, Habte-Gaber
openaire   +2 more sources

Home - About - Disclaimer - Privacy